Walker 256 |
Antitumor assay |
|
|
|
In vivo antitumor activity against rat Walker 256 cells |
469554 |
RBI-1 |
Function assay |
|
|
|
In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells, IC50=0.3μM |
2066989 |
MCF-7 |
Cytotoxicity assay |
|
|
|
Cytotoxic effect on MCF-7 human breast carcinoma cells, IC50=24μM |
8201603 |
ANN-1 |
Cytotoxicity assay |
|
|
|
Cytotoxic effect on v-abl transformed murine ANN-1 cells, IC50=32.5μM |
8201603 |
3T3 |
Cytotoxicity assay |
|
|
|
Cytotoxic effect on 3T3 cells, IC50=39.5μM |
8201603 |
WiDr human colon cells |
Cytotoxicity assay |
|
|
|
Cytotoxic effect on WiDr human colon cells, IC50=40.2μM |
8201603 |
RBL-1 |
Function assay |
|
|
|
In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined, IC50=0.2μM |
8254620 |
HEK293 |
Function assay |
|
|
|
Displacement of [125I]AB-MECA binding to human Adenosine A3 receptor expressed in HEK293 cells, Ki=30μM |
8576921 |
L929 |
Function assay |
|
15 mins |
|
Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by crystal violet staining, EC50=20μM |
9287415 |
L929 |
Function assay |
|
15 mins |
|
Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality preincubated for 15 mins before TNFalpha addition measured after 24 hrs by [methyl-3H]thymidine incorporation assay, EC50=26μM |
9287415 |
L929 |
Function assay |
|
2 hrs |
|
Inhibition of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality treated with drug after 2 hrs of TNFalpha treatment |
9287415 |
L929 |
Function assay |
|
2 hrs |
|
Potentiation of recombinant human TNF-alpha-induced cytotoxicity of mouse L929 cells assessed as survivality treated with drug after 2 hrs of TNFalpha treatment |
9287415 |
3T3/A31 |
Growth inhibition assay |
10 to 100 ug/mL |
72 hrs |
|
Growth inhibition of BALB/c mouse cloned 3T3/A31 cells at 10 to 100 ug/mL after 72 hrs by nigrosin assay |
10096863 |
HeLa |
Function assay |
|
|
|
TP_TRANSPORTER: inhibition of LTC4 uptake in membrane vesicle from MRP1-expressing HeLa cells, Ki=8.1μM |
11306701 |
RAW264.7 |
Function assay |
|
|
|
Inhibition of LPS and INF-gamma-induced NO production in mouse RAW264.7 cells, IC50=26.8μM |
15043424 |
RAW264.7 |
Function assay |
|
|
|
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells, IC50=26.8μM |
16378364 |
HT22 |
Function assay |
|
|
|
Inhibition of glutamate-induced oxytosis of mouse hippocampal HT22 cells, EC50=2.98μM |
16392814 |
Jurkat T |
Function assay |
|
|
|
Activity against hydrogen peroxide induced DNA damage in Jurkat T cells, IC50=5μM |
16392814 |
BM |
Antioxidant assay |
|
|
|
Antioxidant activity in BALB/c mouse BM cells assessed as inhibition of ROS production, IC25=3.5μM |
17166721 |
Sf21 |
Function assay |
|
|
|
Inhibition of human recombinant COX2 expressed in insect Sf21 cells by EIA assay, IC50=28.6μM |
17378609 |
LNCaP |
Function assay |
|
|
|
Decrease in androgen receptor protein expression in LNCaP cells by Western blotting, EC50=25μM |
17383188 |
SKBR3 |
Antiapoptotic assay |
|
72 hrs |
|
Inhibition of HSP70-mediated antiapoptotic activity in human SKBR3 cells assessed as induction of cell growth arrest after 72 hrs by propidium iodide staining-based flow cytometry |
17603540 |
SKBR3 |
Antiapoptotic assay |
|
24 hrs |
|
Inhibition of HSP70-mediated antiapoptotic activity in human SKBR3 cells assessed as increase in caspase-3 activity after 24 hrs by Western blot analysis |
17603540 |
SKBR3 |
Antiapoptotic assay |
|
24 hrs |
|
Inhibition of HSP70-mediated antiapoptotic activity in human SKBR3 cells assessed as induction of caspase-3 cleavage after 24 hrs by Western blot analysis |
17603540 |
SKBR3 |
Antiapoptotic assay |
|
24 hrs |
|
Inhibition of HSP70-mediated antiapoptotic activity in human SKBR3 cells assessed as induction of PARP cleavage after 24 hrs by Western blot analysis |
17603540 |
BGC823 |
Function assay |
50 uM |
|
|
Effect on cell morphology in human BGC823 cells assessed as chromosomal condensations at 50 uM |
17997321 |
BGC823 |
Apoptosis assay |
50 uM |
48 hrs |
|
Induction of apoptotic bodies in human BGC823 cells at 50 uM after 48 hrs |
17997321 |
BGC823 |
Apoptosis assay |
50 uM |
48 hrs |
|
Induction of apoptosis in human BGC823 cells assessed as increase in DNA fragmentation at 50 uM after 48 hrs |
17997321 |
BGC823 |
Apoptosis assay |
100 uM |
48 hrs |
|
Induction of apoptosis in human BGC823 cells assessed as increase in DNA fragmentation at 100 uM after 48 hrs |
17997321 |
RAW264.7 |
Function assay |
|
16 hrs |
|
Inhibition of LPS and INF-alpha-induced nitric oxide production in mouse RAW264.7 cells after 16 hrs, IC50=25μM |
18027905 |
RAW264.7 |
Function assay |
|
|
|
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells, IC50=26.8μM |
18027905 |
BV2 |
Function assay |
|
|
|
Inhibition of LPS-induced NO production in mouse BV2 cells, IC50=29.6μM |
18178435 |
HL60 |
Antiproliferative assay |
30 uM |
48 hrs |
|
Antiproliferative activity against human HL60 cells at 30 uM after 48 hrs by MTS assay |
18258440 |
Jurkat |
Function assay |
50 ug/mL |
1 hr |
|
Inhibition of heat-induced HSP70 expression in human Jurkat cells at 50 ug/mL treated for 1 hr before heat induction by Western blot |
19296652 |
HeLa |
Function assay |
50 ug/mL |
1 hr |
|
Enhancement of HSP27 Ser78 phosphorylation in human HeLa cells at 50 ug/mL treated for 1 hr |
19296652 |
Jurkat |
Function assay |
50 ug/mL |
1 hr |
|
Inhibition of HSF1 binding to heat shock element DNA assessed as HSF1/HSE complex formation in human Jurkat cells at 50 ug/mL treated for 1 hr before heat induction |
19296652 |
Jurkat |
Function assay |
50 ug/mL |
1 hr |
|
Inhibition of of heat-induced increase in nuclear HSF1 protein phosphorylation in human Jurkat cells assessed as decrease in protein mobility at 50 ug/mL treated for 1 hr before heat induction by EMSA |
19296652 |
HeLa |
Function assay |
50 ug/mL |
1 hr |
|
Inhibition of of heat-induced increase in nuclear HSF1 protein phosphorylation in human HeLa cells assessed as decrease in protein mobility at 50 ug/mL treated for 1 hr before heat induction by EMSA |
19296652 |
RAW264.7 |
Antiinflammatory assay |
|
24 hrs |
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess reagent assay, IC50=9.6μM |
19555124 |
MCF7 |
Function assay |
0.5 uM to 10 uM |
24 hrs |
|
Induction of CYP1A1 expression in human MCF7 cells at 0.5 uM to 10 uM after 24 hrs by RT PCR and DNA electrophoresis |
19601638 |
HeLa |
Function assay |
|
|
|
Inhibition of MRP1 transfected in human HeLa cells assessed as inhibition of [3H]LTC4 transport by rapid filtration assay, Ki=2.4μM |
19725578 |
MDCK |
Antiviral assay |
|
|
|
Antiviral activity against influenza A virus H1N1 A/PR/8/34 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect, EC50=43.1μM |
19729316 |
RAW264.7 |
Antiinflammatory assay |
|
24 hrs |
|
Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of LPS-induced nitrite accumulation after 24 hrs by Griess reagent method, IC50=11.4μM |
19778086 |
Vero |
Cytotoxicity assay |
|
3 days |
|
Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay, MNCC<20μM |
19778089 |
Vero |
Cytotoxicity assay |
|
3 days |
|
Cytotoxicity against african green monkey Vero cells after 3 days by MTT assay, MNCC<20μM |
20092288 |
RAW264.7 |
Antiinflammatory assay |
|
24 hrs |
|
Antiinflammatory activity against mouse RAW264.7 cells assessed as Inhibition of LPS-induced nitric oxide production after 24 hrs by ELISA, IC50=32.1μM |
20121165 |
Sf9 |
Function assay |
|
|
|
Inhibition of rat ecto-5'-nucleotidase expressed in Sf9 cells by capillary electrophoresis method, Ki=0.0453μM |
20146483 |
B16-4A5 |
Function assay |
|
72 hrs |
|
Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells after 72 hrs, IC50=15μM |
20189399 |
HUVEC |
Cytoprotective assay |
|
|
|
Cytoprotective activity against H2O2-induced cell injury in HUVEC cells, EC50=18μM |
20621727 |
HEK293 FS |
Function assay |
|
|
|
Inhibition of NOX4 expressed in HEK293 FS cells assessed as H2O2 production by H2O2/Tyr/LPO assay, IC50=0.68μM |
20731357 |
3T3L1 |
Function assay |
10 uM |
|
|
Induction of AMPK phosphorylation in mouse 3T3L1 cells at 10 uM by Western blotting |
20822902 |
3T3L1 |
Function assay |
10 uM |
|
|
Induction of AMPK-mediated ACC phosphorylation in mouse 3T3L1 cells at 10 uM by Western blotting |
20822902 |
3T3L1 |
Function assay |
|
|
|
Inhibition of AMPK-mediated adipocyte differentiation in mouse 3T3L1 cells |
20822902 |
3T3L1 |
Function assay |
|
|
|
Inhibition of PPAR-gamma-mediated adipocyte differentiation in mouse 3T3L1 cells |
20822902 |
RAW264.7 |
Antiinflammatory assay |
|
24 hrs |
|
Antiinflammatory activity against LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO production after 24 hrs, IC50=34.5μM |
20825224 |
HCT116 |
Function assay |
5 uM |
1 hr |
|
Cellular uptake in human HCT116 cells assessed a bright fluorescence light at 5 uM after 1 hr by fluorescence microscopic analysis |
21090565 |
MCF7 |
Function assay |
10 uM |
5 hrs |
|
Cellular uptake in human MCF7 cells assessed as formation of quercetin glucuronide in cell lysates at 10 uM after 5 hrs by HPLC-mass spectrophotometric analysis |
21090565 |
MCF7 |
Function assay |
10 uM |
5 hrs |
|
Cellular uptake in human MCF7 cells assessed as formation of quercetin sulphate in cell lysates at 10 uM after 5 hrs by HPLC-mass spectrophotometric analysis |
21090565 |
MCF7 |
Function assay |
10 uM |
5 hrs |
|
Cellular uptake in human MCF7 cells assessed as formation of oxidised quercetin in cell lysates at 10 uM after 5 hrs by HPLC-mass spectrophotometric analysis |
21090565 |
MCF7 |
Function assay |
10 uM |
5 hrs |
|
Cellular uptake in human MCF7 cells assessed as formation of methylated quercetin in cell lysates at 10 uM after 5 hrs by HPLC-mass spectrophotometric analysis |
21090565 |
RAW264.7 |
Antiinflammatory assay |
1 to 100 uM |
24 hrs |
|
Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as nitrite level at 1 to 100 uM after 24 hrs by Griess method, Activity=1.38μM |
21353543 |
MDCK |
Function assay |
|
|
|
Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining, IC50=6.9μM |
21354800 |
MCF-7 MX |
Function assay |
|
|
|
Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining, IC50=7.6μM |
21354800 |
HepG2(2.2.15) |
Cytotoxicity assay |
|
8 days |
|
Cytotoxicity against human HepG2(2.2.15) cells after 8 days by MTT assay, CC50=38.1μM |
21401115 |
MDA-MB-231 |
Function assay |
20 uM |
30 mins |
|
Increase in c-Fos protein expression in human MDA-MB-231 cells at 20 uM within 30 mins by Western blot analysis |
21652208 |
MDA-MB-231 |
Function assay |
20 uM |
30 mins |
|
Increase in Egr-1 protein expression in human MDA-MB-231 cells at 20 uM within 30 mins by Western blot analysis |
21652208 |
MDA-MB-231 |
Apoptosis assay |
20 uM |
12 hrs |
|
Induction of apoptosis in human MDA-MB-231 cells assessed as cleaved caspase-7 accumulation at 20 uM after 12 hrs by Western blot analysis |
21652208 |
HepG2 |
Cytotoxicity assay |
|
|
|
Cytotoxicity against human HepG2 cells by MTT assay, IC50=30.9μM |
21726077 |
Jurkat |
Function assay |
145 uM |
8 hrs |
|
Inhibition of heat shock-induced HSP70 expression in human Jurkat cells at 145 uM treated 2 hrs before beat shock challenge measured after 8 hrs by Western blotting |
21798748 |
HepG2 |
Function assay |
|
24 hrs |
|
Inhibition of oleic acid-induced triglyceride over-accumulation in human HepG2 cells incubated for 24 hrs relative to untreated control, IC30=14.9μM |
21824690 |
HepG2 |
Antioxidant assay |
|
24 hrs |
|
Antioxidant activity in human HepG2 cells assessed as reduction of oleic acid-induced ROS generation incubated for 24 hrs by DHCF-DA based fluorimetric assay relative to untreated control, IC30=30.8μM |
21824690 |
MDCK |
Antiviral assay |
|
4 days |
|
Antiviral activity against influenza A virus (A/swine/OH/511445/2007(H1N1)) Oh7 infected in MDCK cells assessed as inhibition of viral replication after 4 days by quantitative RT-PCR, ED50=48.2μM |
22115591 |
HCT116 |
Growth inhibition assay |
|
48 hrs |
|
Growth inhibition of human HCT116 cells overexpressing PI3Kalpha H1047R mutant after 48 hrs by MTT assay, IC50=5.7μM |
22212721 |
HCT116 |
Growth inhibition assay |
|
48 hrs |
|
Growth inhibition of human HCT116 cells after 48 hrs by MTT assay, IC50=6.7μM |
22212721 |
HCT116 |
Growth inhibition assay |
|
48 hrs |
|
Growth inhibition of human HCT116 cells overexpressing PI3Kalpha after 48 hrs by MTT assay, IC50=23μM |
22212721 |
HCT116 |
Function assay |
25 uM |
10 mins |
|
Inhibition of PI3Kalpha in human HCT116 cells using [32P]ATP at 25 uM after 10 mins |
22212721 |
HCT116 |
Function assay |
25 uM |
10 mins |
|
Inhibition of PI3Kalpha H1047R mutant in human HCT116 cells using [32P]ATP at 25 uM after 10 mins |
22212721 |
HCT116 |
Function assay |
25 uM |
|
|
Inhibition of PI3Kalpha in human HCT116 cells assessed as inhibition of Akt Ser473 phosphorylation at 25 uM by immunoblot analysis |
22212721 |
HCT116 |
Function assay |
25 uM |
|
|
Inhibition of PI3Kalpha H1047R mutant in human HCT116 cells assessed as inhibition of Akt Ser473 phosphorylation at 25 uM by immunoblot analysis |
22212721 |
human mast cells |
Function assay |
|
|
|
Inhibition of SYK in human mast cells assessed as reduction in mast cell degranulation, EC50=35μM |
22257213 |
Huh7.5.1 |
Antiviral assay |
|
72 hrs |
|
Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay, EC50=19.8μM |
22445328 |
HT22 |
Neuroprotective assay |
25 uM |
24 hrs |
|
Neuroprotective activity against glutamate induced oxidative stress in mouse hippocampal HT22 cells assessed as cell viability at 25 uM after 24 hrs by MTT assay |
22624880 |
22Rv1 |
Antiproliferative assay |
|
|
|
Antiproliferative activity against human 22Rv1 cells incubated up to 144 hrs by Coulter particle count and size analyzer, IC50=15.5μM |
22789812 |
RAW264.7 |
Function assay |
50 uM |
3 hrs |
|
Activation of Nrf2 in mouse RAW264.7 cells assessed as cytosolic accumulation at 50 uM after 3 hrs by Western blotting analysis |
23294286 |
RAW264.7 |
Function assay |
50 uM |
3 hrs |
|
Activation of Nrf2 in mouse RAW264.7 cells assessed as nuclear accumulation at 50 uM after 3 hrs by Western blotting analysis |
23294286 |
ARPE19 |
Function assay |
20 uM |
18 days |
|
Inhibition of intracellular A2E photooxidation in human ARPE19 cells at 20 uM after 18 days |
23346866 |
MV4-11 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human MV4-11 cells harboring FLT3 mutation after 72 hrs by tetrazolium based Ez CyTox cell viability assay, GI50=13.1μM |
23411073 |
RS4:11 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human RS4:11 cells harboring wild type FLT3 after 72 hrs by tetrazolium based Ez CyTox cell viability assay, GI50=21.6μM |
23411073 |
HCT116 |
Cytotoxicity assay |
1 to 100 uM |
12 hrs |
|
Cytotoxicity against human HCT116 cells at 1 to 100 uM after 12 hrs by MTT assay |
23434132 |
MCF7 |
Cytotoxicity assay |
1 to 100 uM |
12 hrs |
|
Cytotoxicity against human MCF7 cells at 1 to 100 uM after 12 hrs by MTT assay |
23434132 |
HTLA |
Function assay |
|
20 mins |
|
Inhibition of CX3CL1-stimulated CX3CR1 in human HTLA cells pre-incubated for 20 mins measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay, IC50=4.5μM |
23437772 |
HTLA |
Function assay |
|
20 mins |
|
Inhibition of CX3CL1-stimulated CX3CR1 in human HTLA cells pre-incubated for 20 mins measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay, IC50=5.01187μM |
23437772 |
HTLA |
Function assay |
|
20 mins |
|
Inhibition of vasopressin-stimulated vasopressin V2 receptor in human HTLA cells pre-incubated for 20 mins measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay, IC50=6.30957μM |
23437772 |
HTLA |
Function assay |
|
20 mins |
|
Inhibition of vasopressin-stimulated vasopressin V2 receptor in human HTLA cells pre-incubated for 20 mins measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay, IC50=7μM |
23437772 |
HTLA |
Function assay |
|
20 mins |
|
Inhibition of CCL22-stimulated CCR4 in human HTLA cells pre-incubated for 20 mins measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay, IC50=10μM |
23437772 |
HTLA |
Function assay |
|
20 mins |
|
Inhibition of CCL22-stimulated CCR4 in human HTLA cells pre-incubated for 20 mins measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay, IC50=10.2μM |
23437772 |
HTLA |
Function assay |
|
20 mins |
|
Inhibition of vasopressin-stimulated vasopressin V2 receptor in human HTLA cells pre-incubated for 20 mins with Tween-80-treated compound solution measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay, IC50=15.2μM |
23437772 |
HTLA |
Function assay |
|
20 mins |
|
Inhibition of vasopressin-stimulated vasopressin V2 receptor in human HTLA cells pre-incubated for 20 mins with Tween-80-treated compound solution measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay, IC50=15.8489μM |
23437772 |
HTLA |
Function assay |
|
20 mins |
|
Inhibition of vasopressin-stimulated vasopressin V2 receptor in human HTLA cells pre-incubated for 20 mins with centrifuged compound solution measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay, IC50=37.8μM |
23437772 |
HTLA |
Function assay |
|
20 mins |
|
Inhibition of vasopressin-stimulated vasopressin V2 receptor in human HTLA cells pre-incubated for 20 mins with centrifuged compound solution measured on day 4 by beta arrestin-recruitment mediated luciferase reporter gene assay, IC50=39.8107μM |
23437772 |
RAW264.7 |
Function assay |
|
24 hrs |
|
Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW264.7 cells after 24 hrs by Griess reaction analysis, IC50=16.4μM |
23517145 |
RAW264.7 |
Function assay |
|
24 hrs |
|
Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs, IC50=1.3μM |
23540981 |
3T3L1 |
Antiobesity assay |
100 uM |
|
|
Antiobesity activity in mouse 3T3L1 cells assessed as reduction of fat accumulation at 100 uM by oil Red O staining-based ELISA |
23642481 |
HT22 |
Neuroprotective assay |
40 uM |
3 hrs |
|
Neuroprotective activity in mouse HT22 cells assessed as t-BOOH-induced toxicity at 40 uM preincubated for 3 hrs followed by t-BOOH induction measured after 9 hrs by MTT assay |
24245939 |
HT22 |
Neuroprotective assay |
40 uM |
3 hrs |
|
Neuroprotective activity in mouse HT22 cells assessed as reduction of t-BOOH-induced oxidative stress at 40 uM preincubated for 3 hrs followed by t-BOOH induction measured after 20 hrs by MTT assay |
24245939 |
HepG2 |
Antioxidant assay |
|
1 hr |
|
Antioxidant activity in human HepG2 cells assessed as inhibition of ABAP-induced intracellular peroxyl radical scavenging activity by measuring ROS production measured every 5 mins for 1 hr by absorbance assay, IC50=11μM |
24471493 |
HT22 |
Neuroprotective assay |
|
24 hrs |
|
Neuroprotective activity in mouse HT22 cells assessed as protection against glutamate-induced oxidative damage after 24 hrs by MTT assay, EC50=3.13μM |
24602904 |
HT22 |
Cytotoxicity assay |
|
24 hrs |
|
Cytotoxicity against mouse HT22 cells after 24 hrs by MTT assay, EC50=11.52μM |
24602904 |
RAW264.7 |
Antiinflammatory assay |
10 uM |
18 hrs |
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNF-alpha secretion at 10 uM after 18 hrs by sandwich ELISA |
24679441 |
BV2 |
Antiinflammatory assay |
|
|
|
Antiinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced nitric oxide production by Griess assay, IC50=10μM |
24707938 |
HT22 |
Neuroprotective assay |
5 uM |
48 hrs |
|
Neuroprotection against glutamate challenged mouse HT22 cells assessed as reduction in cell viability at 5 uM after 48 hrs by MTT assay |
24819955 |
HT22 |
Neuroprotective assay |
25 uM |
24 hrs |
|
Neuroprotective activity against glutamate-induced oxidative stress in mouse HT22 cells assessed as reduction of intracellular ROS formation at 25 uM after 24 hrs by MTT assay |
24900407 |
U2OS |
Function assay |
|
5 hrs |
|
Agonist activity at GPR35 receptor in human U2OS cells coexpressing Gal4-VP16-TEV assessed as beta arrestin translocation after 5 hrs by beta lactamase reporter gene assay, EC50=5.93μM |
24900447 |
HT-29 |
Function assay |
|
10 mins |
|
Agonist activity at GPR35 receptor in human HT-29 cells after 10 mins by dynamic mass redistribution assay, EC50=8.02μM |
24900447 |
HT-29 |
Function assay |
|
10 mins |
|
Desensitization of GPR35 receptor in human HT-29 cells assessed as inhibition of zaprinast-induced dynamic mass redistribution after 10 mins, IC50=15.4μM |
24900447 |
HT-29 |
Function assay |
|
10 mins |
|
Partial agonist activity at GPR35 receptor in human HT-29 cells after 10 mins by dynamic mass redistribution assay |
24900447 |
PC12 |
Neuroprotective assay |
5 uM |
24 hrs |
|
Neuroprotective activity in rat PC12 cells assessed as inhibition H2O2-induced reduction of cell viability at 5 uM after 24 hrs by MTT assay |
24941128 |
HLF1 |
Function assay |
2 to 5 uM |
24 hrs |
|
Inhibition of H2O2-induced oxidative stress in human HLF1 cells assessed as increase in cell viability at 2 to 5 uM pretreated for 24 hrs followed by addition of 300 uM H2O2 for 2.5 hrs |
24996137 |
HL60 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay, IC50=47μM |
25014747 |
HT22 |
Neuroprotective assay |
25 uM |
|
|
Neuroprotective activity in mouse HT22 cells assessed as reduction in glutamate-induced cytotoxicity at 25 uM by MTT assay |
25059502 |
RAW264.7 |
Antiinflammatory assay |
3 uM |
24 hrs |
|
Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as reduction in nitric oxide production at 3 uM after 24 hrs by Griess method based ELISA (Rvb = 52.4 +/- 0.9 uM), Activity=13.5μM |
25106885 |
RAW264.7 |
Antiinflammatory assay |
1.5 uM |
24 hrs |
|
Antiinflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as reduction in nitric oxide production at 1.5 uM after 24 hrs by Griess method based ELISA (Rvb = 52.4 +/- 0.9 uM), Activity=20.8μM |
25106885 |
BV2 |
Function assay |
|
24 hrs |
|
Inhibition of LPS-stimulated NO production in human BV2 cells after 24 hrs by Griess assay, IC50=4.3μM |
25127164 |
HeLa |
Anticancer assay |
|
|
|
Anticancer activity against human HeLa cells by HTS assay, IC50=3.56μM |
25139569 |
NCI-H1792 |
Anticancer assay |
|
|
|
Anticancer activity against human NCI-H1792 cells by HTS assay, IC50=3.85μM |
25139569 |
LOXIMVI |
Anticancer assay |
|
|
|
Anticancer activity against human LOXIMVI cells by HTS assay, IC50=4.65μM |
25139569 |
NCI-H522 |
Anticancer assay |
|
|
|
Anticancer activity against human NCI-H522 cells by HTS assay, IC50=5.77μM |
25139569 |
NCI-H157 |
Anticancer assay |
|
|
|
Anticancer activity against human NCI-H157 cells by HTS assay, IC50=6μM |
25139569 |
A549 |
Anticancer assay |
|
|
|
Anticancer activity against human A549 cells by HTS assay, IC50=6.2μM |
25139569 |
HOP62 |
Anticancer assay |
|
|
|
Anticancer activity against human HOP62 cells by HTS assay, IC50=7.52μM |
25139569 |
H460 |
Anticancer assay |
|
|
|
Anticancer activity against human H460 cells by HTS assay, IC50=9.62μM |
25139569 |
NCI-H1944 |
Anticancer assay |
|
|
|
Anticancer activity against human NCI-H1944 cells by HTS assay, IC50=10.18μM |
25139569 |
M14 |
Anticancer assay |
|
|
|
Anticancer activity against human M14 cells by HTS assay, IC50=12.77μM |
25139569 |
H1299 |
Anticancer assay |
|
|
|
Anticancer activity against human H1299 cells by HTS assay, IC50=13.6μM |
25139569 |
SKBR |
Anticancer assay |
|
|
|
Anticancer activity against human SKBR cells by HTS assay, IC50=16.71μM |
25139569 |
H266 |
Anticancer assay |
|
|
|
Anticancer activity against human H266 cells by HTS assay, IC50=16.87μM |
25139569 |
M4E |
Anticancer assay |
|
|
|
Anticancer activity against human M4E cells by HTS assay, IC50=21.71μM |
25139569 |
Calu1 |
Anticancer assay |
|
|
|
Anticancer activity against human Calu1 cells by HTS assay, IC50=23.58μM |
25139569 |
MDA-MB-231 |
Function assay |
5 uM |
16 hrs |
|
Inhibition of PMA-stimulated NF-kappaB signaling (unknown origin) expressed in MDA-MB-231 cells at 5 uM incubated for 16 hrs by luciferase reporter gene assay |
25190466 |
MDA-MB-231 |
Function assay |
25 uM |
|
|
Inhibition of basal NF-kappaB signaling in human MDA-MB-231 cells assessed as reduction in MMP9 mRNA expression at 25 uM by quantitative RT-PCR method relative to untreated control |
25190466 |
MDA-MB-231 |
Function assay |
25 uM |
|
|
Inhibition of NF-kappaB signaling in human MDA-MB-231 cells assessed as reduction in PMA-stimulated MMP9 mRNA expression at 25 uM pre-incubated before PMA stimulation by quantitative RT-PCR method relative to untreated control |
25190466 |
MDA-MB-231 |
Function assay |
25 uM |
|
|
Inhibition of basal NF-kappaB signaling in human MDA-MB-231 cells assessed as reduction in COX2 mRNA expression at 25 uM by quantitative RT-PCR method relative to untreated control |
25190466 |
MDA-MB-231 |
Function assay |
25 uM |
|
|
Inhibition of NF-kappaB signaling in human MDA-MB-231 cells assessed as reduction in PMA-stimulated COX2 mRNA expression at 25 uM pre-incubated before PMA stimulation by quantitative RT-PCR method relative to untreated control |
25190466 |
MDA-MB-231 |
Function assay |
25 uM |
|
|
Inhibition of NF-kappaB signaling in human MDA-MB-231 cells assessed as reduction in PMA-stimulated MMP9 mRNA expression at 25 uM pre-incubated before PMA stimulation by quantitative RT-PCR method |
25190466 |
MDA-MB-231 |
Function assay |
25 uM |
|
|
Inhibition of NF-kappaB signaling in human MDA-MB-231 cells assessed as reduction in PMA-stimulated COX2 mRNA expression at 25 uM pre-incubated before PMA stimulation by quantitative RT-PCR method |
25190466 |
MDA-MB-231 |
Apoptosis assay |
3.125 to 25 uM |
48 hrs |
|
Induction apoptosis in PMA-stimulated human MDA-MB-231 cells assessed as mitochondrial disruption 3.125 to 25 uM after 48 hrs by JC1 staining based fluorescence assay |
25190466 |
RAW264.7 |
Anti-inflammatory assay |
|
24 hrs |
|
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of lipopolysaccharide-induced nitric oxide production incubated for 24 hrs by Griess reagent based assay, IC50=16.6μM |
25245917 |
HCT116 |
Cytotoxicity assay |
1.25 to 20 uM |
96 hrs |
|
Cytotoxicity against human HCT116 cells at 1.25 to 20 uM after 96 hrs by MTT assay |
25397870 |
HCT116 |
Apoptosis assay |
20 uM |
72 hrs |
|
Induction of apoptosis in human HCT116 cells assessed as PARP cleavage at 20 uM after 72 hrs by immunoblotting |
25397870 |
HCT116 |
Antitumor assay |
80 uM |
4 days |
|
Antitumor activity against human HCT116 cells xenografted in 48 hpf zebrafish embryo assessed as inhibition of cancer cell proliferation at 80 uM treated for 4 days |
25397870 |
C6 |
Function assay |
|
72 hrs |
|
Inhibition of cell proliferation of rat C6 cells assessed as cell viability after 72 hrs by sulforhodamine B assay, IC50=18.38μM |
25442304 |
HCT15 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50=16.35μM |
25906385 |
MCF7 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50=20.9μM |
25906385 |
2008 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human 2008 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50=21.18μM |
25906385 |
A431 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50=23.04μM |
25906385 |
BxPC3 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human BxPC3 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50=24.12μM |
25906385 |
A375 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human A375 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50=25.13μM |
25906385 |
A431 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against cisplatin-resistant human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50=34.37μM |
25906385 |
C13 |
Cytotoxicity assay |
|
72 hrs |
|
Cytotoxicity against human C13 cells assessed as cell growth inhibition after 72 hrs by MTT assay, IC50=37.62μM |
25906385 |
B16-4A5 |
Function assay |
|
72 hrs |
|
Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells after 72 hrs by microplate reader analysis, IC50=15μM |
25987378 |
RAW264.7 |
Anti-inflammatory assay |
|
24 hrs |
|
Anti-inflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production incubated for 24 hrs by Griess reagent based assay, IC50=1.8μM |
26143931 |
BV2 |
Anti-inflammatory assay |
|
24 hrs |
|
Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-stimulated nitric oxide production after 24 hrs by Griess assay, IC50=17.4μM |
26327273 |
LNCAP |
Cytotoxicity assay |
|
3 days |
|
Cytotoxicity against human androgen-dependent LNCAP cells assessed as inhibition of cell viability after 3 days by WST-1 cell proliferation assay, IC50=45.5μM |
26341135 |
BV2 |
Antineuroinflammatory assay |
|
24 hrs |
|
Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-stimulated NO production after 24 hrs by Griess assay, EC50=11μM |
26473791 |
BL21 |
Function assay |
20 uM |
15 mins |
|
Inhibition of recombinant human N-terminal His6-tagged AKR1B10 expressed in Escherichia coli BL21 cells using all-trans-retinal as substrate at 20 uM incubated for 15 mins by HPLC method |
26529431 |
BV2 |
Function assay |
|
24 hrs |
|
Inhibition of LPS-induced nitric oxide production in human BV2 cells after 24 hrs by Griess assay, IC50=8.7μM |
26696523 |
HT22 |
Neuroprotective assay |
25 uM |
24 hrs |
|
Neuroprotective activity against glutamate-induced oxycytotic cell death in mouse HT22 cells assessed as cell viability at 25 uM after 24 hrs by MTT assay |
26886849 |
RAW264.7 |
Anti-inflammatory assay |
|
|
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production by Griess assay, IC50=15μM |
26928174 |
HepG2 |
Antioxidant assay |
|
2.5 hrs |
|
Antioxidant activity in human HepG2 cells assessed as decrease in fluorescence level after 2.5 hrs measured every 5 mins for 1 hr by DCFH-DA staining based fluorescence assay, EC50=4.63μM |
26974372 |
RF/6A |
Antimigratory assay |
|
24 hrs |
|
Antimigratory activity in rhesus monkey RF/6A cells measured after 24 hrs by wound assay, IC50=40μM |
27015547 |
RAW264.7 |
Function assay |
|
24 hrs |
|
Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess assay, IC50=15.9μM |
27177824 |
BV2 |
Antiinflammatory assay |
|
24 hrs |
|
Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production incubated for 24 hrs measured after 15 mins by Griess assay, IC50=15.13μM |
27335254 |
PC12 |
Function assay |
5 uM |
2 hrs |
|
Protective effect against H2O2-induced cell death in rat PC12 cells at 5 uM preincubated for 2 hrs followed by H2O2 addition for 24 hrs by MTT assay |
27343850 |
PC12 |
Antioxidant assay |
2.5 uM |
2 hrs |
|
Antioxidant activity in rat PC12 cells assessed as decrease of H2O2-induced ROS production at 2.5 uM preincubated for 2 hrs followed by H2O2 addition for 24 hrs by DCFH-DA /DAPI-based fluorescence assay |
27343850 |
LNCAP |
Antiproliferative assay |
|
3 days |
|
Antiproliferative activity against human LNCAP cells after 3 days by WST1 assay, IC50=45.5μM |
27476422 |
BV2 |
Antineuroinflammatory assay |
|
24 hrs |
|
Antineuroinflammatory activity in human BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction, IC50=39.46μM |
27623545 |
N9 |
Antineuroinflammatory assay |
|
24 hrs |
|
Antineuroinflammatory activity in mouse N9 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay, IC50=10.22μM |
28073678 |
Escherichia coli competent cells |
Function assay |
|
overnight |
|
Inhibition of amyloid beta (1 to 42) aggregation in Escherichia coli competent cells BL21 (DE3) after overnight incubation by Thioflavin-S steady-state fluorescence assay, IC50=15.3μM |
28128562 |
BV2 |
Antiinflammatory assay |
|
24 hrs |
|
Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitrite production after 24 hrs by Griess assay, IC50=19.11μM |
28165740 |
RAW264.7 |
Function assay |
|
1 hr |
|
Inhibition of LPS-induced NO production in mouse RAW264.7 cells preincubated for 1 hr followed by LPS stimulation measured after 24 hrs by Griess assay, IC50=4.41μM |
28427811 |
LLC-PK1 |
Renoprotective assay |
10 to 100 uM |
2 hrs |
|
Renoprotective activity in pig LLC-PK1 cells assessed as inhibition of cisplatin-induced damage by measuring increase in cell viability at 10 to 100 uM preincubated for 2 hrs followed by cisplatin addition after 24 hrs by Ez-Cytox reagent based assay |
28487074 |
human red blood cells |
Antiplasmodial assay |
|
48 hrs |
|
Antiplasmodial activity against asexual erythrocyte stage of chloroquine-sensitive Plasmodium falciparum 3D7 infected in human red blood cells after 48 hrs by lactate dehydrogenase assay, IC50=17.54μM |
28557449 |
PC12 |
Function assay |
10 uM |
|
|
Inhibition of human amyloid beta (1 to 42) assessed as neuroprotective activity against amyloid beta (1 to 42)-induced toxicity in rat PC12 cells by measuring reduction in cell viability at 10 uM incubated 15 mins prior to amyloid beta (1 to 42) addition |
28559058 |
T47D |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human T47D cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=11μM |
28654265 |
NCI-H460 |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human NCI-H460 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=12μM |
28654265 |
SK-MEL-2 |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human SK-MEL-2 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=12μM |
28654265 |
LN229 |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human LN229 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=12μM |
28654265 |
A549 |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human A549 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=13μM |
28654265 |
MML1 |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human MML1 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=15μM |
28654265 |
BxPC3 |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human BxPC3 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=16μM |
28654265 |
HT-29 |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human HT-29 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=18μM |
28654265 |
COLO201 |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human COLO201 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=19μM |
28654265 |
MDA-MB-231 |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human MDA-MB-231 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=20μM |
28654265 |
U87 |
Cytotoxicity assay |
|
48 hrs |
|
Cytotoxicity against human U87 cells assessed as decrease in cell viability after 48 hrs by MTT assay, IC50=23μM |
28654265 |
LNCAP |
Antiproliferative assay |
|
3 days |
|
Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay, IC50=45.46μM |
28760528 |
PC12 |
Neuroprotective assay |
10 uM |
3 hrs |
|
Neuroprotective activity in rat PC12 cells assessed as decrease in H2O2 mediated apoptosis at 10 uM preincubated for 3 hrs followed by H2O2 challenge measured after 24 hrs by MTT assay |
28803044 |
SH-SY5Y |
Neuroprotective assay |
100 uM |
12 hrs |
|
Neuroprotective activity against H2O2-induced cell death in human SH-SY5Y cells assessed as increase in cell viability at 100 uM pretreated for 12 hrs followed by H2O2 challenge measured after 3 hrs by MTT assay |
28988761 |
BV2 |
Antiinflammatory assay |
|
|
|
Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-stimulated nitric oxide production by Griess reagent based spectrophotometric analysis, IC50=16.3μM |
29122483 |
MDA-MB-468 |
Function assay |
6.6 uM |
|
|
Inhibition of human CYP1B1 expressed in MDA-MB-468 cells assessed as potentiation of cisplatin-induced cytotoxicity by measuring cisplatin EC50 at 6.6 uM (Rvb = 6.70+/- 0.7 uM), EC50=1.1μM |
29150398 |
HEK293 |
Function assay |
|
|
|
Inhibition of human CYP1B1 expressed in HEK293 cells by fluorescence assay, IC50=2.2μM |
29150398 |
MDA-MB-468 |
Function assay |
|
|
|
Inhibition of human CYP1B1 expressed in MDA-MB-468 cells assessed as cell toxicity, IC50=2.2μM |
29150398 |
HEK293 |
Function assay |
20 uM |
|
|
Inhibition of human CYP1A1 transfected in HEK293 cells assessed as protection against CYP1A1 mediated B[a]P toxicity by measuring B[a]P EC50 at 20 uM by MTT assay (Rvb =1.2+/- 0.3 uM), EC50=8.8μM |
29150398 |
HEK293 |
Function assay |
|
|
|
Inhibition of human CYP1A expressed in HEK293 cells by fluorescence assay, IC50=9.9μM |
29150398 |
HEK293 |
Function assay |
|
|
|
Inhibition of human CYP1A1 transfected in HEK293 cells assessed as cell toxicity, IC50=9.9μM |
29150398 |
BV2 |
Antiinflammatory assay |
|
24 hrs |
|
Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by griess assay, IC50=7.2μM |
29303577 |
DAOY |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells |
29435139 |
A673 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells |
29435139 |
SK-N-MC |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells |
29435139 |
NB-EBc1 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells |
29435139 |
SK-N-SH |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells |
29435139 |
NB1643 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells |
29435139 |
LAN-5 |
qHTS assay |
|
|
|
qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells |
29435139 |
K562 |
Cytotoxicity assay |
|
5 days |
|
Cytotoxicity against human K562 cells assessed as inhibition of cell growth after 5 days by MTT assay, IC50=2.5μM |
29553260 |
HepG2 |
Antioxidant assay |
|
60 mins |
|
Antioxidant activity in human HepG2 cells assessed as inhibition of ABAP-induced peroxyl radical generation incubated for 60 mins measured for 60 mins by DCFH-DA probe based fluorescence assay, IC50=12μM |
29553260 |
RAW264.7 |
Cytoprotective assay |
1 pM |
2 hrs |
|
Cytoprotective activity against H2O2-induced oxidative stress in mouse RAW264.7 cells assessed as increase in cell viability at 1 pM incubated for 2 hrs prior to H2O2 addition measured after 24 hrs by MTT assay |
29681148 |
BV2 |
Antiinflammatory assay |
|
24 hrs |
|
Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay, IC50=4.3μM |
30119995 |
BV2 |
Function assay |
|
24 hrs |
|
Inhibition of LPS-induced nitric oxide production in mouse BV2 cells after 24 hrs by Griess assay, IC50=2.4μM |
30132670 |
MCF10A |
Cytotoxicity assay |
|
3 days |
|
Cytotoxicity against human MCF10A cells assessed as decrease in cell viability after 3 days by WST-1 assay, IC50=11.97μM |
30165345 |
PWR-1E |
Cytotoxicity assay |
|
3 days |
|
Cytotoxicity against human PWR-1E cells assessed as decrease in cell viability after 3 days by WST-1 assay, IC50=15.08μM |
30165345 |
LNCAP |
Antiproliferative assay |
|
3 days |
|
Antiproliferative activity against human LNCAP cells after 3 days by WST-1 assay, IC50=45.5μM |
30165345 |
HCT116 |
Function assay |
2.5 uM |
30 mins |
|
Inhibition of IP6K2 in human [3H]-inositol-labelled HCT116 cells assessed as reduction in insp7 levels at 2.5 uM after 30 mins by HPLC analysis |
30624931 |
HEK293 |
Function assay |
2.5 uM |
3.5 hrs |
|
Inhibition of IP6K2 in [3H]-inositol-labelled HEK293 cells assessed as reduction in insp7 levels at 2.5 uM after 3.5 hrs by HPLC analysis relative to control |
30624931 |
3T3-L1 |
Function assay |
2.5 uM |
3 hrs |
|
Activation of AKT activity in mouse 3T3-L1 cells assessed as increase in AKT phosphorylation at T308 residues at 2.5 uM after 3 hrs by Western blot analysis |
30624931 |
3T3-L1 |
Function assay |
1 uM |
3 hrs |
|
Inhibition of IP6K2 in mouse 3T3-L1 cells assessed as AKT phosphorylation at T308 at 1 uM after 3 hrs by Western blot analysis |
30624931 |
HCT116 |
Function assay |
2.5 uM |
3.5 hrs |
|
Inhibition of IP6K2 in human [3H]-inositol-labelled HCT116 cells assessed as reduction in insp7 levels at 2.5 uM after 3.5 hrs by HPLC analysis relative to control |
30624931 |
Jurkat |
Function assay |
|
24 hrs |
|
Inhibition of chymotrypsin-like activity of human 26S proteasome in human Jurkat cells assessed as decrease in AMC hydrolysis using Z-Gly-Gly-Leu-AMC as substrate after 24 hrs by fluorescence based method, IC50=2μM |
30776692 |
Jurkat |
Function assay |
|
2 hrs |
|
Inhibition of chymotrypsin-like activity of purified human 20S proteasome expressed in human Jurkat cells assessed as decrease in AMC hydrolysis using Suc-Leu-Leu-Val-Tyr-AMC as substrate incubated for 2 hrs by fluorescence based method, IC50=3.5μM |
30776692 |
CGN |
Neuroprotective assay |
5 to 100 uM |
24 hrs |
|
Neuroprotective activity in Sprague-Dawley rat CGN cells assessed as protection against H2O2-induced cytotoxicity by measuring increase in cell viability at 5 to 100 uM pre-incubated for 24 hrs before H2O2 stimulation for 24 hrs by MTT assay |
30935792 |
HEK293 |
Function assay |
|
30 mins |
|
Inhibition of human TRPC5 expressed in HEK293 cells assessed as reduction in gadolinium-induced calcium entry after 30 mins by fluo-4 dye based fluorescence assay, IC50=6.5μM |
30943030 |
EPG85-257RDB |
Function assay |
|
72 hrs |
|
Downregulation of ABCB1 gene expression in human EPG85-257RDB cells after 72 hrs by RT-PCR analysis, IC50=12μM |
31103904 |
PC12 |
Neuroprotective assay |
10 uM |
3 hrs |
|
Neuroprotective activity in rat PC12 cells assessed as protection against H2O2-induced cytotoxicity at 10 uM pre-incubated for 3 hrs before H2O2 addition and measured after 12 hrs by MTT assay |
31128990 |
SH-SY5Y |
Neuroprotective assay |
100 uM |
1 hr |
|
Neuroprotective activity against H2O2-induced oxidative stress in human SH-SY5Y cells assessed as reduction in ROS generation at 100 uM preincubated for 1 hr followed by DCFH-DA addition for 30 mins and subsequent co-treatment with compound and H2O2 for 3 |
31158754 |
HT22 |
Neuroprotective assay |
25 uM |
24 hrs |
|
Neuroprotection against glutamate-induced cell death in mouse HT22 cells assessed as increase in cell viability at 25 uM measured after 24 hrs by MTT assay |
31609115 |
HT22 |
Neuroprotective assay |
25 uM |
24 hrs |
|
Neuroprotective activity at mouse HT22 cells assessed as reduction in glutamate-induced oxidative stress by measuring cell viability at 25 uM incubated for 24 hrs by MTT assay |
31609608 |
PANC1 |
Anti-austerity assay |
|
24 hrs |
|
Anti-austerity activity against nutrient-deprived human PANC1 cells assessed as cell death incubated for 24 hrs by WST-8 assay, PC50=21.8μM |
31682126 |